Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining ASA with conditioned medium from adipose tissue-derived MSCs may offer a promising approach for protecting against hippocampal injuries, suggesting potential synergistic therapeutic benefits that merit further investigation.

This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.

This review discusses the use of phosphodiesterase inhibitors for alopecia, finding promising preliminary results with topical caffeine for androgenetic alopecia and telogen effluvium, but limited success in alopecia areata.

In this study, researchers aimed to evaluate the safety and tolerability of low-dose oral minoxidil in adolescents, as existing data on its use in this population are limited and there are no specific pediatric guidelines for prescribing it. Results are not reported.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

This case report describes two transgender men using subdermal testosterone pellets for gender affirmation, finding they tolerated the treatment, but one returned to injections; firm conclusions on pellets' suitability require further study.

This bibliometric analysis found that research on platelet-rich plasma in dermatology and plastic surgery has increased, with hotspots in facial rejuvenation, scar, and alopecia treatment, particularly from the US and Italy.

In this randomized controlled trial, researchers found that a 2.5 mg daily dose of oral minoxidil was more effective than a 1 mg dose in improving hair growth parameters in patients with androgenetic alopecia over three months, with both doses being well tolerated.

This single-patient case study reported promising results for severe, corticosteroid-resistant alopecia areata, with treatment using exosomes derived from mesenchymal stromal cells leading to almost complete hair regrowth in 12 weeks and favorable changes in inflammatory markers, suggesting potential for further investigation.

This review discusses the mechanisms, scientific support, and FDA clearance of photobiomodulation mask devices but reports no new research findings.

This study found that SPARC-overexpressing adipose-derived mesenchymal stem cells significantly improved various aspects of skin wound healing in dogs, including re-epithelialization, collagen deposition, and angiogenesis, showing promise for enhancing treatment effectiveness under different physiological and pathological conditions.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

This review found that dutasteride is more effective than finasteride in increasing hair count and shaft thickness for androgenetic alopecia in men, with potential for reduced systemic side effects through mesotherapy, although further research is needed on long-term safety and dosage.

Low-dose oral minoxidil is as effective as or better than topical minoxidil for hair growth but may cause mild side effects.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This systematic review and meta-analysis suggest that oral minoxidil may be a safer and more effective option for children with hair disorders and refractory hypertension, though further large-scale trials are needed.

This systematic review and meta-analysis found that oral minoxidil improved hair loss symptoms in many patients, with significant improvement in 35%, but 27% experienced adverse events, highlighting the need for further research to confirm its safety and efficacy.

In this study, the researchers reported that baricitinib improved hair loss in a real-world setting for Japanese adults with alopecia areata, with a 64.7% success rate at 60 weeks, though prolonged episodes reduced efficacy. Common side effects were acne and mildly decreased renal function.

In a systematic review and meta-analysis, this study reported that oral spironolactone showed a 56.60% overall improvement in female pattern hair loss, with better results in combination therapy, but emphasized the need for more research due to varied treatment responses and adverse event rates.

This randomized controlled trial found that methotrexate, particularly when combined with low-dose prednisone, was effective in promoting hair regrowth in patients with alopecia areata totalis, with the combination treatment showing higher efficacy and faster results.

This article reviews the efficacy of Finasteride for treating female androgenic alopecia, highlighting increased hair counts and density but reports no new clinical results.

This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.

This study found that recombinant human leukocyte interferon alfa-2a achieved a 64% overall antitumor response rate in patients with early and advanced cutaneous T cell lymphoma and was generally well-tolerated.

This source reports that thymosin beta 4 accelerated dermal wound repair in phase 2 clinical trials for pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds and was well tolerated.

This study found that proretinal nanoparticles, applied topically, are safe and effective for penetration into hair follicles, enhancing retinoid biological activity in the skin while reducing irritation compared to conventional retinal formulations.